GILD:NGS-Gilead Sciences Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 80.70

Change

-0.85 (-1.04)%

Market Cap

USD 105.56B

Volume

7.55M

Yahoo Analyst Target

USD 86.54 (7.24%)

STA Analyst Target

USD 87.10 (7.93%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-02-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TIG TiGenix

+0.92 (+2.20%)

USD 253.14B
AMGN Amgen Inc.

-0.05 (-0.03%)

USD 132.26B
CELG Celgene Corporation

-0.88 (-0.92%)

USD 71.65B
BIIB Biogen Inc.

-7.51 (-2.51%)

USD 61.75B
SHPG Shire plc

-1.24 (-0.92%)

USD 40.67B
VRTX Vertex Pharmaceuticals Incorpo..

-0.22 (-0.14%)

USD 40.65B
REGN Regeneron Pharmaceuticals Inc.

-1.03 (-0.31%)

USD 35.77B
ALXN Alexion Pharmaceuticals Inc.

-2.24 (-1.83%)

USD 26.71B
INCY Incyte Corporation

+0.44 (+0.51%)

USD 18.16B
GRFS Grifols S.A.

-0.07 (-0.30%)

USD 15.66B

ETFs Containing GILD

BBH VanEck Vectors Biotech ET.. 11.56 % 0.35 %

-0.46 (-0.37%)

USD 0.57B
IBB iShares Nasdaq Biotechnol.. 8.30 % 0.47 %

-0.40 (-0.36%)

USD 9.67B
BIB ProShares Ultra Nasdaq Bi.. 6.83 % 0.95 %

-0.48 (-0.81%)

USD 0.42B
UBIO Proshares UltraPro Nasdaq.. 6.74 % 0.95 %

-0.47 (-1.29%)

USD 0.04B
DVP Deep Value 6.05 % 0.00 %

+0.06 (+0.17%)

USD 0.33B
PJP PowerShares Dynamic Pharm.. 5.29 % 0.56 %

+0.22 (+0.33%)

USD 0.62B
HHL:CA Healthcare Leaders Income.. 4.92 % 1.37 %

+0.07 (+0.84%)

CAD 0.26B
PBE PowerShares Dynamic Biote.. 4.90 % 0.58 %

+0.15 (+0.29%)

USD 0.25B
PILL Direxion Daily Pharmaceut.. 4.54 % 0.00 %

+0.72 (+2.49%)

USD 2.97M
MPCT iShares MSCI Global Impac.. 4.28 % 0.49 %

+0.33 (+0.56%)

USD 0.03B
FMK First Trust Mega Cap Alph.. 3.62 % 0.70 %

+0.09 (+0.26%)

USD 0.02B
XLV SPDR Select Sector Fund -.. 3.26 % 0.14 %

+0.61 (+0.72%)

USD 16.33B
IYH iShares U.S. Healthcare 3.12 % 0.44 %

+1.29 (+0.72%)

USD 1.96B
BUZ Buzz US Sentiment Leaders 3.02 % 0.75 %

N/A

USD 0.01B
FHLC Fidelity MSCI Health Care.. 2.80 % 0.08 %

+0.25 (+0.61%)

USD 1.12B
ZVU:CA BMO MSCI USA Value Index .. 2.78 % 0.00 %

+0.61 (+2.88%)

CAD 8.73M
VLUE iShares Edge MSCI USA Val.. 2.78 % 0.15 %

N/A

USD 2.42B
JHMH John Hancock Multifactor .. 2.69 % 0.50 %

+0.22 (+0.69%)

USD 0.04B
FXH First Trust Health Care A.. 2.62 % 0.62 %

+0.33 (+0.46%)

USD 0.99B
FHH:CA First Trust AlphaDEX U.S... 2.61 % 0.77 %

+0.36 (+1.47%)

CAD 7.46M
VHT Vanguard Health Care 2.56 % 0.10 %

+0.92 (+0.58%)

USD 7.35B
RNDV First Trust US Equity Div.. 2.33 % 0.00 %

+0.21 (+0.95%)

USD 0.01B
IXJ iShares Global Healthcare 2.24 % 0.48 %

+0.64 (+0.56%)

USD 1.64B
SDOG ALPS Sector Dividend Dogs 2.21 % 0.40 %

+0.09 (+0.20%)

USD 2.37B
UXM:CA First Asset Morningstar U.. 2.10 % 0.69 %

+0.14 (+0.96%)

CAD 0.06B
UXM.B:CA First Asset Morningstar U.. 2.10 % 0.67 %

N/A

CAD 0.02B
FLAG WeatherStorm Forensic Acc.. 1.12 % 0.85 %

+0.19 (+0.44%)

USD 0.02B
CVY Guggenheim Multi-Asset In.. 1.10 % 0.65 %

+0.07 (+0.30%)

USD 0.31B
FLUS:CA Franklin LibertyQT U.S. E.. 1.07 % 0.28 %

N/A

CAD 0.22B
FTA First Trust Large Cap Val.. 1.02 % 0.62 %

+0.20 (+0.37%)

USD 1.08B
TERM EquityCompass Tactical Ri.. 0.74 % 0.65 %

+0.10 (+0.45%)

USD 0.05B
ERM EquityCompass Risk Manage.. 0.74 % 0.65 %

+0.16 (+0.71%)

USD 0.02B
FAB First Trust Multi Cap Val.. 0.51 % 0.66 %

+0.33 (+0.59%)

USD 0.10B
FEX First Trust Large Cap Cor.. 0.49 % 0.61 %

+0.08 (+0.13%)

USD 1.50B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.65% 69% D+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.65% 69% D+ 85% B
Trailing 12 Months  
Capital Gain 14.78% 57% F 63% D
Dividend Return 2.96% 63% D 69% D+
Total Return 17.74% 58% F 64% D
Trailing 5 Years  
Capital Gain 93.99% 66% D 66% D
Dividend Return 12.52% 43% F 48% F
Total Return 106.51% 68% D+ 66% D
Average Annual (5 Year Horizon)  
Capital Gain 10.41% 54% F 55% F
Dividend Return 11.56% 56% F 55% F
Total Return 1.15% 25% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 33.05% 73% C 40% F
Risk Adjusted Return 34.99% 67% D+ 45% F
Market Capitalization 98.10B 100% A+ 100% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.00 6% F 28% F
Price/Book Ratio 4.24 45% F 27% F
Price / Cash Flow Ratio 1.90 12% F 54% F
Price/Free Cash Flow Ratio 12.01 9% F 42% F
Management Effectiveness  
Return on Equity 20.93% 86% B 86% B
Return on Invested Capital 33.51% 91% A- 93% A
Return on Assets 7.32% 93% A 84% B
Debt to Equity Ratio 90.75% 15% F 28% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

GILD:NGS-Gilead Sciences Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 80.70

Change

-0.85 (-1.04)%

Market Cap

USD 105.56B

Volume

7.55M

Yahoo Analyst Target

USD 86.54 (7.24%)

STA Analyst Target

USD 87.10 (7.93%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-02-16